69
Andros Pharmaceuticals Co.,Ltd
6917.TWO · TWO
$32.20 +1.26% (+$0.40)
1M -1.24%
Market Cap $1.36B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$29.45
8.5% downside
Current Price
$32.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 6917.TWO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Valuation
30 /100
Expensive P/S 6,684.39x
P/B 3.44x
P/E N/A
Growth
22 /100
Declining Rev. growth 75.20%
Book val. growth 79.06%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 4.93%
Net margin 38,561.10%
Op. margin 44,142.90%
Quality
0 /100
Poor ROIC 21.37%
ROA 17.73%
Asset turnover 0.00x
Debt
80 /100
Low Debt/Equity 0.06x
Current ratio 13.81x
Int. coverage -228.04x
Stability
47 /100
Moderate Beta 0.71x
Rev. volatility 17.28%
EPS volatility 75.40%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6917.TWO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ming-Wen Lee
Employees
15
Headquarters
Zhubei